ADA 2022: Tirzepatide Leads to Sustained Weight Loss in Adults With Obesity
Patients receiving the treatment lost, on average, 35 to 52 pounds in the first phase 3 trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.